JP Morgan Chase’s Genomic Health, Inc. GHDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-268,585
| Closed | -$18.2M | – | 6085 |
|
|
2019
Q3 | $18.2M | Buy |
268,585
+247,042
| +1,147% | +$17M | ﹤0.01% | 1658 |
|
|
2019
Q2 | $1.21M | Sell |
21,543
-101,288
| -82% | -$6M | ﹤0.01% | 3729 |
|
|
2019
Q1 | $8.61M | Buy |
122,831
+115,600
| +1,599% | +$8.57M | ﹤0.01% | 2177 |
|
|
2018
Q4 | $466K | Buy |
7,231
+1,086
| +18% | +$76.1K | ﹤0.01% | 4164 |
|
|
2018
Q3 | $432K | Buy |
6,145
+813
| +15% | +$47.6K | ﹤0.01% | 4346 |
|
|
2018
Q2 | $269K | Sell |
5,332
-83
| -2% | -$3.29K | ﹤0.01% | 4441 |
|
|
2018
Q1 | $170K | Sell |
5,415
-109
| -2% | -$3.62K | ﹤0.01% | 4423 |
|
|
2017
Q4 | $189K | Buy |
5,524
+4,475
| +427% | +$143K | ﹤0.01% | 4438 |
|
|
2017
Q3 | $33K | Buy |
1,049
+80
| +8% | +$2.52K | ﹤0.01% | 4555 |
|
|
2017
Q2 | $31K | Buy |
969
+67
| +7% | +$2.12K | ﹤0.01% | 4447 |
|
|
2017
Q1 | $29K | Buy |
902
+44
| +5% | +$1.3K | ﹤0.01% | 4656 |
|
|
2016
Q4 | $26K | Buy |
858
+358
| +72% | +$10.9K | ﹤0.01% | 4661 |
|
|
2016
Q3 | $14K | Sell |
500
-36,972
| -99% | -$1.03M | ﹤0.01% | 4254 |
|
|
2016
Q2 | $970K | Buy |
37,472
+8,843
| +31% | +$235K | ﹤0.01% | 3192 |
|
|
2016
Q1 | $709K | Sell |
28,629
-3,768
| -12% | -$103K | ﹤0.01% | 3216 |
|
|
2015
Q4 | $1.14M | Sell |
32,397
-1,269
| -4% | -$34K | ﹤0.01% | 3063 |
|
|
2015
Q3 | $712K | Sell |
33,666
-170,204
| -83% | -$4.39M | ﹤0.01% | 3279 |
|
|
2015
Q2 | $5.67M | Buy |
203,870
+31,279
| +18% | +$882K | ﹤0.01% | 2318 |
|
|
2015
Q1 | $5.27M | Buy |
172,591
+52,316
| +43% | +$1.66M | ﹤0.01% | 2315 |
|
|
2014
Q4 | $3.85M | Buy |
+120,275
| New | +$3.91M | ﹤0.01% | 2579 |
|
|
2013
Q4 | – | Sell |
-10,116
| Closed | -$309K | – | 4329 |
|
|
2013
Q3 | $309K | Sell |
10,116
-7,087
| -41% | -$237K | ﹤0.01% | 3862 |
|
|
2013
Q2 | $546K | Buy |
+17,203
| New | +$565K | ﹤0.01% | 3570 |
|
JP Morgan Chase's GHDX Position: Q4 2019 in Review
JP Morgan Chase sold out of Genomic Health, Inc. (GHDX) in Q4 2019, closing a stake of 268,585 shares — an estimated $18.2M sold.
JP Morgan Chase first reported a position in GHDX in Q2 2013 and held it in 22 quarters. The position peaked at $18.2M in Q3 2019. 0 funds tracked by Wall St. Rank hold GHDX as of Q4 2019.
- JP Morgan Chase reported no remaining Genomic Health, Inc. position as of Q4 2019 after selling out during the quarter.
- JP Morgan Chase sold 268,585 Genomic Health, Inc. shares in Q4 2019, an estimated $18.2M.
- JP Morgan Chase first reported a position in Genomic Health, Inc. in Q2 2013 and held it in 22 quarters.
- JP Morgan Chase's Genomic Health, Inc. position peaked at $18.2M in Q3 2019.
- 0 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q4 2019.
Based on JP Morgan Chase's 13F filing for Q4 2019, filed 11 Feb 2020.